AD
Publicaties op Oncologisch.com
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Geran...
Tumor Treating Fields plus systemische therapie versus systemische therapie bij NSCLC: LUNAR fase III
Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L definitieve resultaten
Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L definitieve PFS
Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L fase III